Loading...
•
Sep 30, 2022
IRadimed Q3 2022 Earnings Report
IRadimed demonstrated revenue growth and profitability.
Key Takeaways
IRadimed Corporation reported a revenue of $13.4 million, a 23% increase compared to Q3 2021. The company's operating income increased by 32% to $4.1 million, and GAAP diluted EPS grew by 35% to $0.27. Strong demand for IV pump and patient monitor product lines continued with bookings exceeding revenues, adding to the company's backlog.
Revenue was $13.4 million, up 23% year-over-year.
Operating income reached $4.1 million, a 32% increase.
GAAP diluted EPS was $0.27, reflecting a 35% growth.
Operating cash flow was $3.9 million.
Forward Guidance
The Company expects to report revenue of $14.1 million to $14.8 million and GAAP diluted earnings per share of $0.23 to $0.28 per share for the fourth quarter of 2022.
Positive Outlook
- Expects revenue of $14.1 million to $14.8 million for Q4 2022.
- Full-year revenue expected to be $52.5 million to $53.2 million.
- GAAP diluted earnings per share of $0.23 to $0.28 per share expected for Q4 2022.
- Full-year GAAP diluted earnings per share expected to be $0.95 to $1.00.
- Non-GAAP diluted earnings per share of $0.25 to $0.30 expected for Q4 2022.
Challenges Ahead
- Non-GAAP diluted earnings per share guidance excludes stock-based compensation expense.
- Potential disruptions in the limited supply chain for products.
- Reliance on a limited number of products.
- Actions of the FDA or other regulatory bodies that could delay, limit or suspend product development, manufacturing or sales.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...